<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="143049">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01238588</url>
  </required_header>
  <id_info>
    <org_study_id>2010P002213</org_study_id>
    <nct_id>NCT01238588</nct_id>
  </id_info>
  <brief_title>The Effect(s) of Sevelamer Carbonate (Renvela) on Atherosclerotic Plaque Inflammation Judged by FDG-PET Scan</brief_title>
  <official_title>The Effect(s) of Sevelamer Carbonate (Renvela) on Atherosclerotic Plaque Inflammation Judged by FDG-PET Scan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis is that switching calcium based phosphate binders to sevelamer carbonate will
      be associated with less inflammation including less atherosclerotic plaque inflammation
      (inflammation of the vessel walls).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in fluorodeoxyglucose (FDG)-positron emission tomography (PET): FDG-PET/CT dual scan score</measure>
    <time_frame>Baseline and 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in high sensitivity C-Reactive Protein (hs-CRP) level</measure>
    <time_frame>Baseline and 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in interleukin-6 (IL-6) level</measure>
    <time_frame>Baseline and 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Albumin levels</measure>
    <time_frame>Baseline and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythropoiesis Stimulating Agent (ESA) dose requirement</measure>
    <time_frame>Baseline and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin Level</measure>
    <time_frame>Baseline and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of cardiovascular events</measure>
    <time_frame>Baseline and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hemodialysis access stenosis/thrombosis</measure>
    <time_frame>Baseline and 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Dialysis</condition>
  <condition>Cardiovascular Disease</condition>
  <condition>Atherosclerosis</condition>
  <condition>Inflammation</condition>
  <condition>Hyperphosphatemia</condition>
  <arm_group>
    <arm_group_label>Sevelamer Carbonate (Renvela)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Sevelamer Carbonate (Renvela). Information including those from the scans and blood test will be compared before and after treatment with Renvela.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sevelamer Carbonate (Renvela)</intervention_name>
    <description>Patients' will be given doses of Renvela equivalent to their prior dose of calcium based phosphate binders and the dose will be titrated as necessary to achieve phosphate levels recommended by KDOQI guidelines.</description>
    <arm_group_label>Sevelamer Carbonate (Renvela)</arm_group_label>
    <other_name>Sevelamer carbonate</other_name>
    <other_name>Renvela</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A signed consent form;

          -  Male or Female, 50 years or older;

          -  Diagnosed with end stage renal disease (ESRD), on maintenance hemodialysis for at
             least three (3) months;

          -  On calcium-based phosphate binders;

          -  Subject must be able to understand and provide informed consent;

          -  No known contraindications to therapy with sevelamer carbonate.

        Exclusion Criteria:

          -  Any patient with a medical condition or taking any medications that would be
             contraindicated with the use of sevelamer carbonate, such as history of bowel
             obstruction;

          -  History of severe allergic reactions to the study medication;

          -  History of active infection (other than a simple respiratory tract infection) or
             acute gouty attack within 2 weeks prior to enrollment;

          -  Known serological positivity for Human Immunodeficiency Virus (HIV), Hepatitis B
             surface Antigen (HBsAg), or Hepatitis C Virus Antibody (HCV Ab) except dose with
             normal liver function tests (AST, ALT, Bilirubin, and Alkaline Phophatase) and no
             history of cirrhosis;

          -  Elevation of liver function tests at time of entry (Aspartate Aminotransferase (AST)
             and/or Alanine Aminotransferase (ALT) &gt; 2 times the upper limit of normal);

          -  History of drug, alcohol, or chemical abuse within 6 months prior to enrollment;

          -  History of malignancy except those adequately treated, has completed treatment and
             clinically in remission for more than 6 month; adequately treated in-situ cervical
             carcinoma, or adequately treated basal or squamous cell carcinoma of the skin;

          -  History of an inflammatory disease such as systemic lupus erythematosus (SLE),
             rheumatoid arthritis or ulcerative colitis except those in remission for more than 6
             months;

          -  Patients currently on sevelamer carbonate or sevelamer chloride or history of taking
             them for more than a week in the past three months;

          -  Patients receiving chronic anti-inflammatory therapy;

          -  Patients in whom FDG-PET/CT dual scans are contraindicated.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kambiz Zandi-Nejad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kambiz Zandi- Nejad, MD</last_name>
    <phone>617-732-5700</phone>
    <phone_ext>34769</phone_ext>
    <email>kzandinejad@partners.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fresenius Boston-TKC</name>
      <address>
        <city>Bostone</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kambiz Zandi-Nejad, MD</last_name>
      <phone>617-732-5700</phone>
      <phone_ext>34769</phone_ext>
      <email>kzandinejad@partners.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kambiz ZANDI-NEJAD, MD</last_name>
      <phone>617-732-5700</phone>
      <phone_ext>34769</phone_ext>
      <email>kzandinejad@partners.org</email>
    </contact>
    <contact_backup>
      <last_name>Joseph P Curran, RN</last_name>
      <phone>617-983-4480</phone>
    </contact_backup>
    <investigator>
      <last_name>Kambiz ZANDI-NEJAD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>BWH/FH/DCI Outpatient Dialysis Unit</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kambiz ZANDI-NEJAD, MD</last_name>
      <phone>617-732-5700</phone>
      <phone_ext>34769</phone_ext>
      <email>kzandinejad@partners.org</email>
    </contact>
    <contact_backup>
      <last_name>Joseph P Curran, RN</last_name>
      <phone>617-983-4480</phone>
    </contact_backup>
    <investigator>
      <last_name>Kambiz ZANDI-NEJAD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fresenius Framingham (#1109)</name>
      <address>
        <city>Framingham</city>
        <state>Massachusetts</state>
        <zip>01701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kambiz Zandi-Nejad, MD</last_name>
      <phone>617-732-5700</phone>
      <phone_ext>34769</phone_ext>
      <email>kzandinejad@partners.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fresenius Marlborough (#3448)</name>
      <address>
        <city>Marlborough</city>
        <state>Massachusetts</state>
        <zip>01752</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kambiz Zandi-Nejad, MD</last_name>
      <phone>617-732-5700</phone>
      <phone_ext>34769</phone_ext>
      <email>kzandinejad@partners.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fresenius Medford Dialysis (#1246)</name>
      <address>
        <city>Medford</city>
        <state>Massachusetts</state>
        <zip>02155</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kambiz Zandi-Nejad, MD</last_name>
      <phone>617-732-5700</phone>
      <phone_ext>34769</phone_ext>
      <email>kzandinejad@partners.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fresenius Quincy (#1610)</name>
      <address>
        <city>Quincy</city>
        <state>Massachusetts</state>
        <zip>02169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kambiz Zandi-Nejad, MD</last_name>
      <phone>617-732-5700</phone>
      <phone_ext>34769</phone_ext>
      <email>kzandinejad@partners.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fresenius Roxbury (#1630)</name>
      <address>
        <city>Roxbury</city>
        <state>Massachusetts</state>
        <zip>02119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kambiz Zandi-Nejad, MD</last_name>
      <phone>617-732-5700</phone>
      <phone_ext>34769</phone_ext>
      <email>kzandinejad@partners.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DCI Dialysis Unit-Somerville</name>
      <address>
        <city>Somerville</city>
        <state>Massachusetts</state>
        <zip>02145</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kambiz Zandi-Nejad, MD</last_name>
      <phone>617-732-5700</phone>
      <phone_ext>34769</phone_ext>
      <email>kzandinejad@partners.org</email>
    </contact>
    <contact_backup>
      <last_name>Joseph P Curran, RN</last_name>
      <phone>617-983-4480</phone>
      <email>jpcurran@partners.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Fresenius QCDC-Weymouth (#9144)</name>
      <address>
        <city>Weymouth</city>
        <state>Massachusetts</state>
        <zip>02190</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kambiz Zandi-Nejad, MD</last_name>
      <phone>617-732-5700</phone>
      <phone_ext>34769</phone_ext>
      <email>kzandinejad@partners.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <lastchanged_date>October 5, 2015</lastchanged_date>
  <firstreceived_date>November 9, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Kambiz Zandi-Nejad, MD</investigator_full_name>
    <investigator_title>Instructor in Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Hyperphosphatemia</mesh_term>
    <mesh_term>Plaque, Atherosclerotic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sevelamer</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
